Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kimiyo Tabata
Observed names:
K. Tabata,
Kimiyo M Tabata
Institution:
Eisai (Japan)
Observed institution:
Eisai (Japan)
ORCID:
0000-0001-5116-4740
Observed ORCID:
0000-0001-5116-4740
OpenAlex ID:
A5028733380
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
2019
·
Yu Kato
, Kimiyo Tabata
, et al.
·
PLoS ONE
·
495
PDF
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model
2018
·
Takayuki Kimura
, Yu Kato
, et al.
·
Cancer Science
·
363
PDF
Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response
2016
·
Y. Kato
, X. Bao
, et al.
·
Annals of Oncology
·
49
PDF
A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency
2024
·
Shinji Kohsaka
, Shigehiro Yagishita
, et al.
·
npj Precision Oncology
·
24
Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors
2015
·
Yu Kato
, Kimiyo Tabata
, et al.
·
Molecular Cancer Therapeutics
·
22
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
2023
·
Yuki Niwa
, Keito Adachi
, et al.
·
Molecular Cancer Therapeutics
·
17
PDF
Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding
2013
·
Tadashi Nagakura
, Kimiyo Tabata
, et al.
·
Thrombosis Research
·
13
Abstract 4089: Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model
2019
·
Taro Semba
, Kimiyo Tabata
, et al.
·
Cancer Research
·
6
Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2023
·
Ken Ito
, Masayuki Yamaguchi
, et al.
·
Molecular Cancer Therapeutics
·
4
36 Suppression of metastasis and improvement of drug distribution by eribulin mesylate
2014
·
Y. Ozawa
, K. Okamoto
, et al.
·
European Journal of Cancer
·
3
Supplementary Figures from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
2025
·
Yuki Niwa
, Keito Adachi
, et al.
Supplementary Figure Legends from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
2025
·
Yuki Niwa
, Keito Adachi
, et al.
Table S1-S3 from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
2025
·
Yuki Niwa
, Keito Adachi
, et al.
Supplementary Materials and Methods from Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti–PD-1 Antibody
2025
·
Yuki Niwa
, Keito Adachi
, et al.
Supplemental Table S4 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Data from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S7 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S8 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S2 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S4 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S3 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplemental Table S5 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S6 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S5 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Supplementary Fig. S10 from Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities
2024
·
Ken Ito
, Masayuki Yamaguchi
, et al.
Show more works
View as search
Works count:
46
Citation count:
996
H-index:
7
I10-index:
7
Year
Topic
Type